Ranbaxy Laboratories reported on Wednesday that it would not be able to launch a generic version of a urinary drug in the United States as per schedule in the absence of a final approval from the regulator.

Ranbaxy is India’s largest drug maker and they expected to launch the cheaper copycat version of Astellas Pharma’s (4503.T) Flomax in the United States this month.

“We regret that despite our best efforts we were not able to get an approval for the subject product, and hence will not be in a position to launch the product,” Ranbaxy said in a statement, referring to the drug.” They did not give any reasons for not getting the approval.